Liver failure
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.(1)Aged 18 to 70 years (inclusive); 2.(2) Chronic liver disease, regardless of etiology; 3.(3) Meet the diagnostic criteria of the Asia-Pacific Guidelines for Acute-on-chronic Liver Failure: extreme fatigue, obvious gastrointestinal symptoms; PTA =40% or INR =1.5; rapidly deepening jaundice, serum TBil =85µmol/L with or without complications such as hepatic encephalopathy, ascites, hepatorenal syndrome, etc. 4.(4) Patients with confirmed, clinically diagnosed, or suspected invasive fungal infection; 5.(5) Continuous use of voriconazole for more than 3 days; 6.(6) Negative urine or serum pregnancy test within 24 hours before the first dose (for women of childbearing age); 7.(7) Willing to receive treatment and sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1.(1)Pregnant women; 2.(2) Untreated HIV infection; 3.(3) Patients with other chronic end-stage organ failure; 4.(4) Patients with advanced malignant tumors; 5.(5) Patients with intolerance or poor compliance; 6.(6) Patients who are unable or unwilling to provide informed consent or follow the requirements of the study; 7.(7) Patients with a history of allergy to voriconazole and in addition to the above exclusion criteria, patients who meet any of the contraindications in the experimental drug instructions;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma voriconazole concentrations in patients 0-30 minutes after asunaprevirDPMAS treatment;Drug dosage for DPMAS treatment of wastewater;The Cmin of voriconazole on the second day of DPMAS treatment was calculated, and the difference between the measured Cmin and the Cmin simulated by the Monte Carlo curve was calculated; | — |
Countries
China
Contacts
The First Affiliated Hospital of Xi'an Jiaotong University